Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 10.38
- Piotroski Score 5.00
- Grade Overweight
- Symbol (NBIX)
- Company Neurocrine Biosciences, Inc.
- Price $115.20
- Changes Percentage (0.12%)
- Change $0.14
- Day Low $114.14
- Day High $115.90
- Year High $157.98
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/28/2024
- Fiscal Year End N/A
- Average Stock Price Target $143.00
- High Stock Price Target $200.00
- Low Stock Price Target $100.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $3.69
- Trailing P/E Ratio 36.58
- Forward P/E Ratio 36.58
- P/E Growth 36.58
- Net Income $249.70 M
Income Statement
Quarterly
Annual
Latest News of NBIX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History
Neurocrine Biosciences disappoints investors with Phase 2 data on schizophrenia treatment. The study showed an 18.2-point reduction in symptoms with NBI-1117568 compared to 10.8 points with placebo, a...
By Yahoo! Finance | 1 month ago -
Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX)
On August 15, 2024, Director William Rastetter sold 14,250 shares of Neurocrine Biosciences Inc, owning 37,491 shares now. The company focuses on treatments for neurological and endocrine-related dise...
By Yahoo! Finance | 1 month ago -
Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History - Yahoo Finance
Neurocrine Biosciences and Diurnal Ltd. showcased their neuroendocrinology pipeline at ENDO 2024, featuring primary data from Phase 3 studies of crinecerfont for congenital adrenal hyperplasia. Result...
By Yahoo! Finance | 3 months ago
